Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nebius Group NV (NBIS) vs Sanofi SA (SNY) Price & Performance

Nebius Group NVTrade

Price performance (Past 24H)

Key statistics

Nebius Group NV vs Sanofi SA — how do they compare? Nebius Group NV trades at $254.75 (market cap $49.06B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 2.1× Nebius Group NV's market cap, and Sanofi SA pays a 5.55% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.

NBISSNY
Market Cap
$49.06B$104.30B
Sector
TechnologyHealth
52-Week High
$286.69$52.34
52-Week Low
$64.06$41.33
Enterprise Value
$49.26B$124.19B
Dividend Yield
5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nebius Group NV

NBIS stock trades at $249.82, up 35.69% in 24 hours, driven by strong Q2 2026 earnings beats and positive AI cloud demand sentiment. Technicals are bearish with key support at $190 and resistance at $196, while fundamentals show rapid revenue growth but negative EPS and high valuation multiples. Recent news highlights Michael Burry's short position alongside upbeat analyst coverage.

Outlook is mixed: high growth in AI infrastructure offers upside, but execution risks, negative earnings, and stretched valuations pose significant challenges. Analyst consensus is bullish with an $248.73 price target, yet competitive pressures and capital intensity require careful monitoring for sustained shareholder value.

Sanofi SA

SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.

The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nebius Group NV

Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.

Read more on NBIS

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY